It must, therefore, be acknowledged that both the discovery study by Hoste et al. and the external validation study by Bagshaw et al. have heterogeneity in their study populations only for patients with KIDGO stages II–III, and it is not known whether the same diagnostic efficacy of urinary CCL14 exists for different AKI subtypes (e.g., sepsis) as well as for patients with different AKI stages. Here, CCL14 is linked to Sepsis.